Comparing Facial Aging Between Identical Twins With 3D Imaging

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPonsky Facial Aesthetics And Plastic Surgery, Llc

About this trial

Identical twins share the same genes, which makes them a powerful way to study how lifestyle and environment - rather than genetics - affect how faces age. This study builds on a landmark 2009 twin study by using modern three-dimensional (3D) facial imaging, which measures facial shape and volume precisely instead of relying on regular photographs. The study will also look at whether use of GLP-1 weight-loss medications (such as semaglutide or tirzepatide), sometimes associated with facial changes informally called "Ozempic face," is related to measurable differences in facial aging.

The study will enroll adult identical twin pairs attending the Twins Days Festival in Twinsburg, Ohio, in August 2026. Participation takes about 30 minutes and happens in a single visit at the festival study booth. Each twin will complete a questionnaire about lifestyle, environment, and medical history (such as sun exposure, smoking, sleep, and medication use) and have a 3D image of their face taken with a non-contact camera system. There is no treatment, no medication, no blood draw or biological sample, and no follow-up visit. Researchers will then compare facial measurements within each twin pair to learn which lifestyle and environmental factors are linked to visible facial aging.

Eligibility criteria

Qualifiers

Adults aged 18 years or older

Members of a monozygotic (identical) twin pair, with both twins present and willing to participate

Able to provide written informed consent in English

Disqualifiers

Age under 18 years

Inability or unwillingness to provide informed consent

Facial conditions or recent facial surgery that, in the investigator's judgment, would prevent standardized imaging

Pregnancy, by self-report

Trial design

Treatments tested in this trial

  • GLP-1 Receptor Agonists

Treatment groups

200 Participants
are divided into 1 treatment group